What is the story about?
The Central Drugs Standard Control Organisation (CDSCO) has intensified monitoring of the supply chain of GLP-1 weight-loss drugs, given its unauthorised sale and misuse, sources told CNBC-TV18.
CDSCO conducted inspections at 49 entities, including online pharmacies, wholesalers, retailers, and wellness clinics, sources said.
It has issued notices for irregularities in the sale and promotion.
The CDSCO has also issued an advisory reiterating a ban on surrogate advertising and off-label promotion.
The advisory said that these medicines are prescription-only and should be used strictly under the guidance of qualified specialists.
The CDSCO has warned of regulatory action against violations.
Recently, a new global study raised concerns over the long-term use of popular weight-loss and diabetes drugs such as Ozempic, Wegovy, and Mounjaro. The study warned that even temporary discontinuation could significantly increase the risk of heart attack, stroke, and death.
The study, published in BMJ Medicine, tracked more than 3.3 lakh patients with Type 2 diabetes over a three-year period.
According to the findings, patients who continued treatment saw the greatest benefit, with cardiovascular risk falling by nearly 18%. However, those who discontinued the drugs for one to two years experienced a 14% to 22% increase in risk — effectively erasing earlier gains. Even a six-month break was enough to reduce protection, highlighting how quickly the benefits can fade.
CDSCO conducted inspections at 49 entities, including online pharmacies, wholesalers, retailers, and wellness clinics, sources said.
It has issued notices for irregularities in the sale and promotion.
The CDSCO has also issued an advisory reiterating a ban on surrogate advertising and off-label promotion.
The advisory said that these medicines are prescription-only and should be used strictly under the guidance of qualified specialists.
The CDSCO has warned of regulatory action against violations.
Recently, a new global study raised concerns over the long-term use of popular weight-loss and diabetes drugs such as Ozempic, Wegovy, and Mounjaro. The study warned that even temporary discontinuation could significantly increase the risk of heart attack, stroke, and death.
The study, published in BMJ Medicine, tracked more than 3.3 lakh patients with Type 2 diabetes over a three-year period.
According to the findings, patients who continued treatment saw the greatest benefit, with cardiovascular risk falling by nearly 18%. However, those who discontinued the drugs for one to two years experienced a 14% to 22% increase in risk — effectively erasing earlier gains. Even a six-month break was enough to reduce protection, highlighting how quickly the benefits can fade.
